NanoSphere Releases Their First Research Report

NanoSphere Health Sciences (CSE:NSHS) was featured in an report by Ubika, regarding the company’s first research report for their patented cannabis nanoparticle delivery system. NanoSphere is a healthcare technology company that specializes in the controlled, rapid delivery of therapeutic agents through their patented smart nanoparticles. The company will be pursuing additional opportunities in the nutraceutical, pharmaceutical, over-the-counter medication, animal health and skin care markets.

The research report released by NanoSphere suggests that the delivery system improves the effectiveness and onset time of cannabinoids and other therapeutic compounds. The system is able to provide a powerful and long-lasting effect that requires low and precise dosages of bioactive compounds, such as THC and CBD, into the bloodstream. The bioactive compounds then target receptors directly, which provides an increase in potency and a decreased risk of the patient suffering from any adverse effects.

Moving forward, NanoSphere will continue to grow its presence and its cannabis brand, Evolve, in the cannabis space. Additionally, the company has established a first mover advantage in the market with its transdermal product platform and will be supplementing its position with the launch of their intranasal and intraoral products. NanoSphere and its operating partners are currently generating revenue in Colorado and expect sales to commence in California and Arizona before the end of Q3 2018. The company is also expecting sales to start in Canada and is six other US states in 2019.

To read the full report, click here.

Click here to connect with NanoSphere Health Sciences (CSE:NSHS) for an Investor Presentation. 

Source: files.constantcontact.com